Identification

Name
Celecoxib
Accession Number
DB00482  (APRD00373)
Type
Small Molecule
Groups
Approved, Investigational
Description

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and is also used to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. Celecoxib is available by prescription in capsule form [7].

By inhibiting prostaglandin synthesis, non-steroidal anti-inflammatory drugs (NSAIDs) cause mucosal damage, ulceration and ulcer complication throughout the gastrointestinal tract. Celecoxib, however, poses less of an ulceration risk, owing to its decreased effect on gastric mucosal prostaglandin synthesis, when compared to placebo [8].

Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies [7].

Structure
Thumb
Synonyms
  • Celecoxib
  • Célécoxib
  • Celecoxibum
  • P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
External IDs
SC 58635 / YM 177
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act CelecoxibCapsule200 mgOralActavis Pharma Company2014-11-21Not applicableCanada
Act CelecoxibCapsule100 mgOralActavis Pharma Company2014-11-21Not applicableCanada
CelebrexCapsule200 mg/1OralAidarex Pharmaceuticals LLC1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralA-S Medication Solutions1998-10-022018-05-10Us50090 063020180907 15195 nnetjq
CelebrexCapsule100 mg/1OralCardinal Health1998-10-02Not applicableUs55154 362120180913 8702 1e282s0
CelebrexCapsule200 mg/1OralClinical Solutions Wholsesale1998-10-022017-06-22Us58118 152520180913 8702 1pvzm27
CelebrexCapsule100 mgOralPfizer1999-04-19Not applicableCanada
CelebrexCapsule200 mg/1OralKeltman Pharmaceuticals Inc.2006-03-01Not applicableUs
CelebrexCapsule200 mg/1OralPhysicians Total Care, Inc.1998-10-02Not applicableUs54868 410120180907 15195 wldzf8
CelebrexCapsule100 mg/1OralH.J. Harkins Company1998-10-02Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-celecoxibCapsule200 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-celecoxibCapsule100 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Ag-celecoxibCapsule100 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-celecoxibCapsule200 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Apo-celecoxibCapsule200 mgOralApotex Corporation2014-11-17Not applicableCanada
Apo-celecoxibCapsule100 mgOralApotex Corporation2014-11-17Not applicableCanada
Auro-celecoxibCapsule200 mgOralAuro Pharma Inc2015-12-02Not applicableCanada
Auro-celecoxibCapsule100 mgOralAuro Pharma Inc2015-12-02Not applicableCanada
Bio-celecoxibCapsule100 mgOralBiomed Pharma2014-12-05Not applicableCanada
Bio-celecoxibCapsule200 mgOralBiomed Pharma2014-12-05Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
NuDroxiPAKCelecoxib (200 mg/1) + Capsaicin (0.25 mg/1mL) + Menthol (60 mg/1mL) + Methyl salicylate (250 mg/1mL)KitNucare Pharmaceuticals,inc.2018-02-08Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CapxibCelecoxib (200 mg/1) + Capsaicin (0.0375 mg/1) + Menthol (50 mg/1)KitOral; TopicalMas Management Group2016-04-082018-01-01Us
LidoXibCelecoxib (200 mg/1) + Lidocaine (40 mg/1g) + Menthol (10 mg/1g)KitOralMas Management Group2015-06-032018-01-01Us
OnsenalCelecoxib (200 mg)CapsuleOralPfizer2003-10-172011-04-06Eu
OnsenalCelecoxib (200 mg)CapsuleOralPfizer2003-10-172011-04-06Eu
OnsenalCelecoxib (400 mg)CapsuleOralPfizer2003-10-172011-04-06Eu
OnsenalCelecoxib (200 mg)CapsuleOralPfizer2003-10-172011-04-06Eu
OnsenalCelecoxib (400 mg)CapsuleOralPfizer2003-10-172011-04-06Eu
OnsenalCelecoxib (200 mg)CapsuleOralPfizer2003-10-172011-04-06Eu
International/Other Brands
Articox (Keyfarm) / Articoxib (Nabiqasim) / Artiflex (Standpharm) / Artilog (Pfizer) / Artix (Pharmalab) / Artrixib (Intipharma) / Blockten (Infarmasa) / Caditar (Farmindustria) / Cefinix (Farmacoop) / Celact (Sun) / Celebra (Pfizer) / Celebrex / Onsenal (Pfizer) / Valdyne (Pfizer)
Categories
UNII
JCX84Q7J1L
CAS number
169590-42-5
Weight
Average: 381.372
Monoisotopic: 381.075882012
Chemical Formula
C17H14F3N3O2S
InChI Key
RZEKVGVHFLEQIL-UHFFFAOYSA-N
InChI
InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
IUPAC Name
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide
SMILES
CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F

Pharmacology

Indication

For the relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis [Label].

Associated Conditions
Pharmacodynamics

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). The inhibition of prostaglandin E2 synthesis which (a mediator of pain) results from the inhibition of COX-2, and helps to alleviate pain symptoms [Label].

Celecoxib is used to treat rheumatoid arthritis, osteoarthritis, and familial adenomatous polyposis (FAP). Due to its lack of platelet effects, celecoxib is not a substitute for aspirin for cardiovascular prophylaxis [Label].

Mechanism of action

Unlike most NSAIDs, which inhibit both types of cyclooxygenases (COX-1 and COX-2), celecoxib is a selective noncompetitive inhibitor of cyclooxygenase-2 (COX-2) enzyme [Label].

The mechanism of action of celecoxib is the inhibition of prostaglandin synthesis through COX-2 inhibition [Label].

COX-2 is expressed heavily in inflamed tissues where it is induced by inflammatory mediators. COX-2 also plays physiological roles in a limited number of tissues, including those of the female reproductive tract, the kidney, and possibly the vascular endothelium [13].

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
U3-phosphoinositide-dependent protein kinase 1
inhibitor
Human
UCarbonic anhydrase 2
inhibitor
Human
UCarbonic anhydrase 3
inhibitor
Human
UATP-binding cassette sub-family B member 5
substrate
Human
UATP-binding cassette sub-family G member 2Not AvailableHuman
UMultidrug resistance protein 1Not AvailableHuman
Absorption

Easily absorbed in the gastrointestinal tract. When a single dose of 200 mg is given to healthy subjects, peak plasma levels occur 3 hours after an oral dose. The peak plasma level is 705 ng/mL. Absolute bioavailability studies have not been conducted. When multiple doses are given, steady-state is reached on or before Day 5. When taken with a high-fat meal, peak plasma levels are delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20% [Label].

A meta-analysis of pharmacokinetic studies has suggested an approximately 40% higher AUC (area under the curve) of celecoxib in black patients compared to Caucasians for unknown reasons [13].

Volume of distribution

The apparent volume of distribution at steady state (Vss/F) is about 400 L, suggesting extensive distribution into various tissues. Celecoxib is not preferentially bound to red blood cells [Label].

Protein binding

97%, primarily to albumin in healthy patients [Label].

Metabolism

Celecoxib metabolism is primarily mediated via cytochrome P450 2C9, in the liver. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. These metabolites are inactive as COX-1 or COX-2 inhibitors. Patients who are known or suspected to be P450 2C9 poor metabolizers, based on a previous history, should be administered celecoxib with caution as they may have abnormally high plasma levels due to their reduced metabolic clearance [Label].

When celecoxib capsules were taken with a high-fat meal, peak plasma levels were delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20% [Label].

Route of elimination

Celecoxib is eliminated predominantly by hepatic metabolism with little (<3%) unchanged drug recovered in the urine and feces. 57% of the oral dose is excreted in the feces and 27% is excreted into the urine. The primary metabolite in urine and feces was the carboxylic acid metabolite (73%). The amount of glucuronide in the urine is low [Label].

Half life

The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption [Label].

Clearance

Apparent clearance (CL/F), single oral 200 mg dose, healthy subjects = 27.7 L/hr [Label].

Toxicity

LD50 in both the rat and dog is >2000 mg/kg [Label].

It is not advisable to administer celecoxib in patients with renal impairment or advanced hepatic impairment [Label]. Symptoms of overdose celecoxib include breathing difficulties, coma, drowsiness, gastrointestinal bleeding, high blood pressure, kidney failure, nausea, sluggishness, stomach pain, and vomiting [11]. Because serious GI tract ulcerations and bleeding can occur without preceding symptoms, physicians should monitor for signs/symptoms of GI bleeding [Label].

Multiple studies have been performed on the coadministration of celecoxib and proton pump inhibitors [9], [10]. It has been concluded that in patients at high risk of both cardiovascular and gastrointestinal events who require concomitant aspirin and NSAID, celecoxib in addition to a proton-pump inhibitor is the preferred treatment to reduce the risk of recurrent episodes of upper gastrointestinal bleeding [10].

A note on cardiovascular safety:

The concerns about the cardiovascular thrombotic risk of COX-2 selective NSAIDS emerged in the early 2000’s. Following an FDA Advisory Committee meeting in 2005, in which data from large clinical outcome trials in a wide range of indications and epidemiology studies of several individual NSAIDs were analyzed, the FDA concluded that the risk for cardiovascular thrombotic events was apparent for both COX-2 selective NSAIDs and nonselective NSAIDs [11].

Importantly, postmarketing cardiovascular outcomes trial (PRECISION) found that the lowest dose of celecoxib was similar to moderate doses of naproxen and ibuprofen in regards to cardiovascular (CV) safety [11]. Patients with recent cardiovascular events such as acute MI, coronary revascularization, or coronary stent placement were not studied in the PRECISION trial. NSAID use is not advisable in these groups of patients [11].

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Celecoxib Action PathwayDrug action
Celecoxib Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C9CYP2C9*3(A;C) / (C;C)C AlleleEffect Directly StudiedPatients with this genotype have reduced metabolism of celecoxib.Details
Cytochrome P450 2C9CYP2C9*6Not Available818delAEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*15Not Available485C>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*25Not Available353_362delAGAAATGGAAEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*35Not Available374G>T / 430C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*2Not Available430C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*4Not Available1076T>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*5Not Available1080C>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*8Not Available449G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*11Not Available1003C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*12Not Available1465C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*13Not Available269T>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*14Not Available374G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*16Not Available895A>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*18Not Available1075A>C / 1190A>C  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*26Not Available389C>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*28Not Available641A>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*30Not Available1429G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*33Not Available395G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Celecoxib.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Celecoxib.
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Celecoxib.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Celecoxib.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Celecoxib.
5-androstenedioneThe metabolism of 5-androstenedione can be decreased when combined with Celecoxib.
6-Deoxyerythronolide BThe metabolism of Celecoxib can be decreased when combined with 6-Deoxyerythronolide B.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Celecoxib.
AbacavirCelecoxib may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Abciximab.
Food Interactions
  • Take without regard to meals.
  • Taking this product with a high-fat meal will delay the Cmax, but total absorption will be increased by 10 to 20%.

References

Synthesis Reference
US5466823
General References
  1. Malhotra S, Shafiq N, Pandhi P: COX-2 inhibitors: a CLASS act or Just VIGORously promoted. MedGenMed. 2004 Mar 23;6(1):6. [PubMed:15208519]
  2. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247-55. [PubMed:10979111]
  3. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17;352(11):1071-80. Epub 2005 Feb 15. [PubMed:15713944]
  4. Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown RM: Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology (Oxford). 2007 Jan;46(1):135-40. Epub 2006 Jun 15. [PubMed:16777855]
  5. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31;355(9):873-84. [PubMed:16943400]
  6. Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E: Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol. 2002 Oct;54(4):423-9. [PubMed:12392591]
  7. Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE: Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb. [PubMed:22336956]
  8. Hawkey CJ: COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol. 2001 Oct;15(5):801-20. doi: 10.1053/bega.2001.0236. [PubMed:11566042]
  9. Gwee KA, Goh V, Lima G, Setia S: Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. J Pain Res. 2018 Feb 14;11:361-374. doi: 10.2147/JPR.S156938. eCollection 2018. [PubMed:29491719]
  10. Chan FKL, Ching JYL, Tse YK, Lam K, Wong GLH, Ng SC, Lee V, Au KWL, Cheong PK, Suen BY, Chan H, Kee KM, Lo A, Wong VWS, Wu JCY, Kyaw MH: Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet. 2017 Jun 17;389(10087):2375-2382. doi: 10.1016/S0140-6736(17)30981-9. Epub 2017 Apr 11. [PubMed:28410791]
  11. FDA drug safety, June 28 2018 [Link]
  12. Medscape drug reference [Link]
  13. Pfizer Medical Information [Link]
External Links
Human Metabolome Database
HMDB0005014
KEGG Drug
D00567
KEGG Compound
C07589
PubChem Compound
2662
PubChem Substance
46505596
ChemSpider
2562
BindingDB
11639
ChEBI
41423
ChEMBL
CHEMBL118
Therapeutic Targets Database
DAP000737
PharmGKB
PA448871
HET
CEL
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Celecoxib
ATC Codes
L01XX33 — CelecoxibG01AE10 — Combinations of sulfonamidesM01AH01 — Celecoxib
AHFS Codes
  • 28:08.04.08 — Cyclooxygenase-2 (COX-2) Inhibitors
PDB Entries
1oq5 / 3kk6 / 3ln1 / 4fim / 5jw1
FDA label
Download (174 KB)
MSDS
Download (51.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentStage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
0CompletedBasic ScienceBMI >30 kg/m21
0RecruitingBasic ScienceMajor Depressive Disorder (MDD)1
0RecruitingPreventionHealthy Volunteers1
0RecruitingTreatmentMetastatic Carcinoma in the Liver / Recurrent Colorectal Carcinoma / Stage IV Colorectal Cancer AJCC v7 / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer AJCC v71
0TerminatedBasic ScienceBone Ingrowth / Pain NOS1
1Active Not RecruitingTreatmentGlioblastomas1
1Active Not RecruitingTreatmentNeuroblastomas1
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers7
1CompletedOtherHealthy Male Volunteers1
1CompletedOtherHealthy Volunteers1
1CompletedOtherMigraines1
1CompletedPreventionColorectal Cancers / Precancerous Conditions1
1CompletedPreventionHead and Neck Carcinoma1
1CompletedPreventionProstate Cancer1
1CompletedTreatmentAdvanced Esophageal Cancers / Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura / Lung Cancer Non-Small Cell Cancer (NSCLC) / Pleural Mesotheliomas / Primary Small Cell Lung Cancers1
1CompletedTreatmentChildhood Malignant Fibrous Histiocytoma of Bone / Sarcomas1
1CompletedTreatmentColorectal Cancers / Severe or persistent diarrhea1
1CompletedTreatmentEpithelial Malignancies / Melanoma / Pleural Malignancy / Sarcomas1
1CompletedTreatmentEsophageal Cancers / Lung Cancers / Malignant Pleural Mesothelioma (MPM) / Sarcomas / Thymic Carcinoma1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHereditary Nonpolyposis / Neoplasms, Colorectal1
1CompletedTreatmentLung Cancers3
1CompletedTreatmentNeoplasms, Hepatic1
1CompletedTreatmentNon-Small Cell Lung Cancer Recurrent / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1CompletedTreatmentPain NOS1
1CompletedTreatmentPostoperative pain1
1CompletedTreatmentRelapsed Multiple Myeloma1
1CompletedTreatmentStage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
1CompletedTreatmentTuberculosis Infection1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific3
1CompletedTreatmentPainful musculoskeletal conditions1
1Not Yet RecruitingPreventionActinic Keratosis (AK) / Therapy, Photodynamic1
1RecruitingBasic ScienceElectrophysiologic Property of Brain1
1RecruitingOtherHealthy Volunteers1
1RecruitingTreatmentBladder Cancers1
1RecruitingTreatmentGliomas1
1TerminatedBasic ScienceHealthy Volunteers1
1TerminatedTreatmentCancer, Breast1
1TerminatedTreatmentEpithelial Malignancies / Melanoma / Pleural Malignancy / Sarcomas1
1TerminatedTreatmentAdvanced thymic carcinoma / Esophageal Cancers / Lung Cancers / Mesolthelioma / Thoracic Sarcomas1
1TerminatedTreatmentHealthy Volunteers1
1TerminatedTreatmentInflammatory Reaction1
1TerminatedTreatmentMalignant Neoplasm of Pancreas1
1WithdrawnBasic ScienceLung Cancer Non-Small Cell Cancer (NSCLC)1
1WithdrawnTreatmentMelanoma / Neoplasms Metastasis / Neoplasms, Germ Cell and Embryonal / Sarcomas1
1, 2Active Not RecruitingTreatmentColorectal Cancers / Malignant Neoplasm of Colon1
1, 2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas Metastatic to Peritoneal Surface / Malignant Peritoneal Mesothelioma / Peritoneal Carcinomatosis1
1, 2CompletedBasic ScienceCardiovascular Disease (CVD) / High Blood Pressure (Hypertension) / Obstructive Sleep Apnea (OSA) / Strokes1
1, 2CompletedBasic ScienceMouth Neoplasms1
1, 2CompletedPreventionBiomarker Change Linked to Breast Cancer1
1, 2CompletedPreventionCancer, Breast1
1, 2CompletedPreventionTobacco Use Disorders1
1, 2CompletedTreatmentAdvanced Melanoma1
1, 2CompletedTreatmentCervical Cancers1
1, 2CompletedTreatmentCervix Neoplasms1
1, 2CompletedTreatmentLiver Cancer1
1, 2CompletedTreatmentLung Cancers2
1, 2CompletedTreatmentMalignancies1
1, 2CompletedTreatmentNasopharyngeal Carcinoma1
1, 2CompletedTreatmentNeoplasms, Colorectal1
1, 2Not Yet RecruitingTreatmentArthritis / BMI >30 kg/m2 / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
1, 2SuspendedTreatmentCancers of Non-thoracic Origin With Metastases to the Lungs or Pleura / Esophageal Cancers / Lung Cancers / Malignant Pleural Mesothelioma (MPM) / Melanoma / Sarcomas / Thoracic Sarcomas / Thorasic Cancers / Thymic Carcinoma1
1, 2TerminatedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1, 2Unknown StatusTreatmentCancer of the Head / Cancer of the Larynx / Cancer of the Neck / Cancer of the Pharynx / Paranasal Sinus Neoplasms1
1, 2Unknown StatusTreatmentHead and Neck Carcinoma1
1, 2WithdrawnTreatmentLiver Cancer1
2Active Not RecruitingTreatmentColorectal Cancers1
2Active Not RecruitingTreatmentEsophageal Cancers1
2Active Not RecruitingTreatmentFallopian Tube Cancer / Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
2Active Not RecruitingTreatmentFamilial Adenomatous Polyposis (FAP)1
2Active Not RecruitingTreatmentNeurofibromatosis 11
2Active Not RecruitingTreatmentTonsillectomy1
2CompletedNot AvailableMetastatic Hormone Refractory Prostate Cancer1
2CompletedDiagnosticNeoplasms1
2CompletedPreventionCancer, Breast2
2CompletedPreventionCervical Cancers / Cervical Carcinoma / Cervical Intraepithelial Neoplasia Grade 2 / Cervical Intraepithelial Neoplasia Grade 2/3 / Cervical Intraepithelial Neoplasia Grade 3 / Stage 0 Cervical Cancer1
2CompletedPreventionColorectal Cancers1
2CompletedPreventionEsophageal Cancers1
2CompletedPreventionHead and Neck Carcinoma1
2CompletedPreventionHead and Neck Carcinoma / Precancerous Conditions1
2CompletedPreventionLung Cancers2
2CompletedPreventionMonoclonal Gammopathy of Undetermined Significance (MGUS) / Multiple Myeloma (MM) / Smoldering Multiple Myeloma (SMM)1
2CompletedPreventionNo Evidence of Disease2
2CompletedPreventionNon-Melanomatous Skin Cancer1
2CompletedPreventionOral Mucositis1
2CompletedPreventionPrecancerous Conditions1
2CompletedSupportive CarePain NOS1
2CompletedSupportive CareTonsillitis1
2CompletedTreatmentAdenotonsillectomy / Postoperative pain / Tonsillectomy1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentAnaplastic Glioma of Brain / Brain Cancer / Glioblastoma Multiforme (GBM)1
2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
2CompletedTreatmentBrain Stem Gliomas1
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentCancer, Breast4
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCarcinoma, Colorectal / Colorectal Adenomas1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric / Leukemias / Malignant Lymphomas / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentColorectal Cancers4
2CompletedTreatmentDental Pain2
2CompletedTreatmentEsophageal Cancers2
2CompletedTreatmentFacial Pain1
2CompletedTreatmentGastric Carcinoma / Gastroesophageal Junction Carcinoma1
2CompletedTreatmentHead and Neck Carcinoma1
2CompletedTreatmentHead and Neck Carcinoma / Lung Cancers1
2CompletedTreatmentLocally Advanced Rectal Cancer1
2CompletedTreatmentLung Cancers5
2CompletedTreatmentMacular Degeneration1
2CompletedTreatmentMalignant Neoplasm of Pancreas2
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNon Muscle Invasive Bladder Cancer1
2CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNon-Small Cell Lung Cancer Recurrent / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer2
2CompletedTreatmentOsteoarthritis (OA)1
2CompletedTreatmentPain NOS1
2CompletedTreatmentPain, Acute2
2CompletedTreatmentPostoperative pain1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRecurrent Respiratory Papillomatosis1
2CompletedTreatmentRenal Cell Adenocarcinoma / Stage IV Renal Cell Cancer1
2CompletedTreatmentSarcomas1
2CompletedTreatmentSchizophrenic Disorders1
2CompletedTreatmentTemporomandibular Joint Disorders1
2Not Yet RecruitingTreatmentAnatomic Stage IV Breast Cancer AJCC / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Triple -Negative Breast Cancer1
2Not Yet RecruitingTreatmentKnee Replacement Surgery / Manipulation1
2Not Yet RecruitingTreatmentSpinal Muscular Atrophy (SMA)1
2RecruitingPreventionOral Squamous Cell Carcinoma1
2RecruitingPreventionPain, Neuropathic1
2RecruitingSupportive CareCancer of the Breast / Cancer, Breast / Malignant Neoplasm of Female Breast1
2RecruitingTreatmentAllodynia / Migraine With Aura / Migraine Without Aura1
2RecruitingTreatmentAnkylosing Spondylitis (AS)1
2RecruitingTreatmentCarcinoma of Buccal Mucosa / Head and Neck Carcinoma / Oral Squamous Cell Carcinoma / Tongue Cancers1
2RecruitingTreatmentChemotherapy Effect / Malignant Neoplasm of Pancreas1
2RecruitingTreatmentColon Carcinoma1
2RecruitingTreatmentKnee Osteoarthritis (Knee OA)2
2RecruitingTreatmentKnee Replacement Surgery / Postoperative pain1
2RecruitingTreatmentLymphangioleiomyomatosis (LAM)1
2RecruitingTreatmentMalignancies1
2RecruitingTreatmentMedulloblastomas1
2RecruitingTreatmentRecurrent Neuroblastoma1
2RecruitingTreatmentThyroid Eye Disease1
2RecruitingTreatmentTumors, Solid1
2TerminatedNot AvailableUterine Malignancies1
2TerminatedPreventionCancer, Breast1
2TerminatedPreventionPancreas Neoplasms1
2TerminatedTreatmentAdenocarcinoma of the Prostate / Prostate Cancer1
2TerminatedTreatmentBrain and Central Nervous System Tumors1
2TerminatedTreatmentBreast Cancer, Metastatic / Cancer treatment1
2TerminatedTreatmentCancer of the Ovary / Primary Peritoneal Cavity Cancer1
2TerminatedTreatmentCancer, Breast2
2TerminatedTreatmentColorectal Cancers1
2TerminatedTreatmentColorectal Cancers / Familial Adenomatous Polyposis (FAP)1
2TerminatedTreatmentEsophageal Cancers1
2TerminatedTreatmentHead and Neck Carcinoma / Lung Cancers1
2TerminatedTreatmentKnee Osteoarthritis (Knee OA)1
2TerminatedTreatmentLaryngeal Papilloma1
2TerminatedTreatmentLung Cancers1
2TerminatedTreatmentMetastatic Cancers / Prostate Cancer1
2TerminatedTreatmentMetastatic Colorectal Cancers1
2TerminatedTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
2TerminatedTreatmentOvarian Carcinoma1
2TerminatedTreatmentProstate Cancer1
2TerminatedTreatmentRecurrent Colon Carcinoma / Recurrent Rectal Carcinoma / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2TerminatedTreatmentRheumatoid Arthritis1
2Unknown StatusPreventionHead and Neck Carcinoma1
2Unknown StatusSupportive CareKnee Osteoarthritis (Knee OA)1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors2
2Unknown StatusTreatmentColorectal Cancers1
2Unknown StatusTreatmentHead and Neck Carcinoma1
2Unknown StatusTreatmentLung Cancers2
2Unknown StatusTreatmentProstate Cancer2
2WithdrawnBasic ScienceCarcinoma, Breast1
2WithdrawnPreventionNon-Melanomatous Skin Cancer1
2WithdrawnTreatmentHigh-Grade Squamous Intraepithelial Lesions / Stage 0 Cervical Cancer1
2WithdrawnTreatmentMetastatic Colorectal Cancers1
2WithdrawnTreatmentPreeclampsia1
2, 3CompletedPreventionDuodenal Neoplasms / Duodenal Polyps / Familial Adenomatous Polyposis (FAP)1
2, 3CompletedPreventionRecurrent Bladder Cancer1
2, 3CompletedTreatmentProstate Cancer1
2, 3RecruitingTreatmentProstate Cancer1
2, 3TerminatedTreatmentOral Cavity Cancer1
2, 3WithdrawnPreventionPrecancerous Conditions1
3Active Not RecruitingTreatmentBack Pain Lower Back1
3Active Not RecruitingTreatmentCancer, Breast1
3Active Not RecruitingTreatmentColorectal Cancers1
3Active Not RecruitingTreatmentKnee Osteoarthritis (Knee OA) / Osteoarthritis (OA)1
3CompletedPreventionAlzheimer's Disease (AD)1
3CompletedPreventionMalignant Neoplasm of Colon / Rectal Carcinoma1
3CompletedPreventionPrevention / Smoking1
3CompletedSupportive CareCelebrex / Pelubiprofen / Rheumatoid Arthritis1
3CompletedTreatmentAcute Gouty Arthritis1
3CompletedTreatmentAcute Post-surgical Pain1
3CompletedTreatmentAnkylosing Spondylitis (AS)2
3CompletedTreatmentAnterior Cruciate Ligament Injury1
3CompletedTreatmentArthritis / Bleeding Ulcers1
3CompletedTreatmentArthritis / Cardiovascular Disease (CVD) / Cerebrovascular Disorders1
3CompletedTreatmentArthritis / Gastric Ulcer (GU)1
3CompletedTreatmentBack Pain Lower Back2
3CompletedTreatmentColorectal Adenomas1
3CompletedTreatmentColorectal Cancers2
3CompletedTreatmentHigh Blood Pressure (Hypertension)2
3CompletedTreatmentKnee Osteoarthritis (Knee OA)6
3CompletedTreatmentMacular Degeneration1
3CompletedTreatmentMemory Disorders1
3CompletedTreatmentMetastatic Breast Cancer (MBC)1
3CompletedTreatmentOsteoarthritis (OA)11
3CompletedTreatmentOsteoarthritis (OA) / Pain NOS1
3CompletedTreatmentOsteoarthritis (OA) / Peptic Ulcers1
3CompletedTreatmentOther Acute Postoperative Pain2
3CompletedTreatmentPain NOS1
3CompletedTreatmentPain, Acute2
3CompletedTreatmentPharyngitis1
3CompletedTreatmentPost Operative Pain1
3CompletedTreatmentPostoperative pain1
3CompletedTreatmentRheumatoid Arthritis, Juvenile1
3Not Yet RecruitingTreatmentBipolar Disorder (BD) / Postpartum Depression1
3RecruitingPreventionHysteroscopy2
3RecruitingTreatmentBipolar Disorder (BD) / Depression / Depression, Bipolar / Moods Disorders1
3RecruitingTreatmentInfluenza, Human1
3RecruitingTreatmentLiver Cancer / Postoperative pain1
3RecruitingTreatmentNasopharyngeal Carcinoma1
3RecruitingTreatmentOpioids Use / Shoulder Pain1
3SuspendedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3TerminatedPreventionAdenomatous Polyposis Coli1
3TerminatedPreventionColorectal Cancers1
3TerminatedPreventionOsteoarthritis (OA)1
3TerminatedSupportive CareCancer, Breast / Colorectal Cancers / Pain NOS1
3TerminatedTreatmentLung Cancers1
3Unknown StatusNot AvailableMalignant Neoplasm of Pancreas1
3Unknown StatusTreatmentColon Neoplasms1
3Unknown StatusTreatmentHead and Neck Carcinoma1
3Unknown StatusTreatmentLocalized Primary Osteoarthritis of Hip / Localized Primary Osteoarthritis of Knee1
3Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4Active Not RecruitingSupportive CareReverse or Primary Total Shoulder / Rotator Cuff- Full Thickness- Repair1
4CompletedNot AvailableCelecoxib / Function / Minimally Invasive Total Knee Arthroplasty / Pain Management1
4CompletedNot AvailableGastroduodenal Ulcers1
4CompletedBasic ScienceHigh Blood Pressure (Hypertension)1
4CompletedBasic ScienceIschaemic Heart Diseases / Osteoarthritis (OA)1
4CompletedPreventionArthroscopy2
4CompletedPreventionHealthy Volunteers1
4CompletedPreventionOsteoarthritis (OA) / Rheumatoid Arthritis1
4CompletedPreventionPeptic Ulcers1
4CompletedPreventionPostoperative pain1
4CompletedTreatmentAnalgesics1
4CompletedTreatmentAnkle Sprains1
4CompletedTreatmentAnkylosing Spondylitis (AS) / Inflammatory Reaction1
4CompletedTreatmentBack Pain1
4CompletedTreatmentBack Pain Lower Back2
4CompletedTreatmentBowel Diseases, Inflammatory1
4CompletedTreatmentColorectal Cancers1
4CompletedTreatmentColorectal Disorders1
4CompletedTreatmentCoronary Arteriosclerosis1
4CompletedTreatmentCyclooxygenase 2 Inhibitors / Postoperative pain / Thyroidectomy1
4CompletedTreatmentHealthy Volunteers2
4CompletedTreatmentHepatocellular,Carcinoma1
4CompletedTreatmentHypertension and Coronary Artery Disease1
4CompletedTreatmentInflammatory Reaction / Pain NOS1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)7
4CompletedTreatmentKnee Osteoarthritis (Knee OA) / Osteoarthritis, Hip1
4CompletedTreatmentMagnetic Resonance Imaging (MRI) / Spondylarthropathy1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain NOS1
4CompletedTreatmentOsteoarthritis (OA)2
4CompletedTreatmentOsteoarthritis (OA) / Rheumatoid Arthritis1
4CompletedTreatmentOsteoarthritis, Hip1
4CompletedTreatmentPostoperative Pain Management / Total Knee Arthroplasty (TKA)1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentRheumatoid Arthritis, Juvenile1
4CompletedTreatmentRotator Cuff Syndrome1
4Enrolling by InvitationTreatmentBile Duct Carcinoma / Malignant Neoplasm of Pancreas1
4Enrolling by InvitationTreatmentNonspecific Pain Post Traumatic Injury1
4Not Yet RecruitingPreventionPain NOS1
4Not Yet RecruitingTreatmentAnkylosing Spondylitis (AS)1
4Not Yet RecruitingTreatmentPerineal Pain1
4Not Yet RecruitingTreatmentPharmacokinetics of Celecoxib in Children1
4Not Yet RecruitingTreatmentPostoperative pain1
4Not Yet RecruitingTreatmentPostoperative pain / Renal Stones1
4RecruitingBasic ScienceCardiovascular Disease (CVD) / Rheumatoid Arthritis1
4RecruitingPreventionColposcopy1
4RecruitingTreatmentAnkylosing Spondylitis (AS)1
4RecruitingTreatmentAnkylosing Spondylitis (AS) / Spondyloarthritis, Axial1
4RecruitingTreatmentColon Cancer Stage1
4RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
4RecruitingTreatmentLigament Injury1
4RecruitingTreatmentOsteoarthritis (OA)1
4RecruitingTreatmentOsteoarthritis of the Hands1
4RecruitingTreatmentPain Management1
4RecruitingTreatmentRheumatoid Arthritis1
4TerminatedNot AvailableFamilial Adenomatous Polyposis (FAP)1
4TerminatedTreatmentBack Pain Lower Back Chronic1
4TerminatedTreatmentChronic Low Back Pain With a Neuropathic Component1
4TerminatedTreatmentCrohn's Disease (CD)1
4TerminatedTreatmentKnee Osteoarthritis (Knee OA)1
4TerminatedTreatmentOsteoarthritis (OA) / Pain NOS1
4TerminatedTreatmentPain NOS1
4TerminatedTreatmentUterine Artery Embolization / Uterine Leiomyomas1
4Unknown StatusTreatmentAngioplasty, Transluminal, Percutaneous Coronary / Coronary Artery Restenosis1
4Unknown StatusTreatmentKnee Osteoarthritis (Knee OA)1
4Unknown StatusTreatmentPain NOS1
4WithdrawnTreatmentBenign Prostatic Hyperplasia (BPH)1
4WithdrawnTreatmentPost Operative Pain Control1
4WithdrawnTreatmentUreteral Calculus1
Not AvailableCompletedNot AvailableAnkylosing Spondylitis (AS)1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableOsteoarthritis (OA)1
Not AvailableCompletedNot AvailablePatients With Traumatic Pain, Post-surgical Pain and Tooth Extract Pain1
Not AvailableCompletedDiagnosticGonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P) / Menstrual Cycles (Total Length, Bleeding Days) / Ovulation (Follicular Rupture Yes/no)1
Not AvailableCompletedDiagnosticLuteal Development / Ovulation1
Not AvailableCompletedPreventionAlzheimer's Disease (AD) / Dementias1
Not AvailableCompletedPreventionIUD Insertion Pain1
Not AvailableCompletedScreeningHealthy Volunteers1
Not AvailableCompletedTreatmentAntiphospholipid Antibody Syndrome1
Not AvailableCompletedTreatmentHip Labral Tears1
Not AvailableCompletedTreatmentIntracerebral Hemorrhage1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedTreatmentLung Cancers1
Not AvailableCompletedTreatmentPain NOS1
Not AvailableCompletedTreatmentSchizophrenic Disorders1
Not AvailableCompletedTreatmentSpinal Stenosis of Lumbar Region1
Not AvailableCompletedTreatmentSquamous Cell Carcinoma (SCC)1
Not AvailableCompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
Not AvailableNot Yet RecruitingPreventionPrevention of Post Operative Ileus1
Not AvailableNot Yet RecruitingTreatmentPulpitis dental1
Not AvailableRecruitingNot AvailableKnee Osteoarthritis (Knee OA)1
Not AvailableRecruitingPreventionOssification, Heterotopic1
Not AvailableRecruitingTreatmentBack Pain Lower Back1
Not AvailableRecruitingTreatmentDepression / Inflammatory Reaction1
Not AvailableRecruitingTreatmentHip Pain Chronic1
Not AvailableRecruitingTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableRecruitingTreatmentStiffness Following Total Knee Arthroplasty1
Not AvailableRecruitingTreatmentTreatment Outcomes1
Not AvailableTerminatedNot AvailableOsteoarthritis (OA)1
Not AvailableTerminatedNot AvailableRheumatoid Arthritis, Juvenile1
Not AvailableTerminatedTreatmentColorectal Cancers1
Not AvailableTerminatedTreatmentColorectal Cancers / Malignant Neoplasm of Colon1
Not AvailableTerminatedTreatmentDiabetic Nephropathies1
Not AvailableTerminatedTreatmentPain NOS1
Not AvailableUnknown StatusNot AvailableHip Fractures1
Not AvailableUnknown StatusTreatmentAcute Respiratory Distress Syndrome (ARDS) / Blunt Chest Trauma1
Not AvailableUnknown StatusTreatmentHealthy Volunteers1
Not AvailableUnknown StatusTreatmentPostoperative pain2
Not AvailableWithdrawnPreventionBrca1 Mutation Carrier / Brca2 Mutation Carrier / Cancer of the Ovary1
Not AvailableWithdrawnSupportive CareCachexia / Cancer of the Ovary / Malignant Lymphomas / Melanoma (Skin) / Pain NOS / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableWithdrawnTreatmentBladder Cancers1

Pharmacoeconomics

Manufacturers
  • Gd searle llc
Packagers
  • 4uOrtho LLC
  • Apotheca Inc.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Blenheim Pharmacal
  • Bryant Ranch Prepack
  • Cardinal Health
  • Direct Pharmaceuticals Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • GD Searle LLC
  • H.J. Harkins Co. Inc.
  • Innoviant Pharmacy Inc.
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Physicians Total Care Inc.
  • Prepackage Specialists
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
KitOral; Topical
CapsuleOral100 mg
CapsuleOral100 mg/1
CapsuleOral200 mg/1
CapsuleOral200 mg
CapsuleOral400 mg/1
CapsuleOral50 mg/1
Kit100 mg/1
KitOral
Kit
CapsuleOral400 mg
Prices
Unit descriptionCostUnit
Celebrex 400 mg capsule6.78USD capsule
Celebrex 200 mg capsule4.52USD capsule
Celebrex 100 mg capsule2.75USD capsule
Celebrex 50 mg capsule1.26USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5972986No1999-10-262018-04-14Us
CA2267186No2002-05-142017-10-14Canada
CA2177576No1999-10-262014-11-14Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityPoorly solublehttps://www.lclabs.com/products/c-1502-celecoxib
logP3.53MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.00503 mg/mLALOGPS
logP3.99ALOGPS
logP4.01ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)10.7ChemAxon
pKa (Strongest Basic)-0.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area77.98 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity92.23 m3·mol-1ChemAxon
Polarizability35.2 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9713
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.9287
P-glycoprotein inhibitor INon-inhibitor0.8619
P-glycoprotein inhibitor IINon-inhibitor0.792
Renal organic cation transporterNon-inhibitor0.8582
CYP450 2C9 substrateNon-substrate0.6237
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.5751
CYP450 1A2 substrateInhibitor0.7805
CYP450 2C9 inhibitorInhibitor0.6172
CYP450 2D6 inhibitorNon-inhibitor0.8594
CYP450 2C19 inhibitorInhibitor0.7169
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7392
Ames testNon AMES toxic0.7185
CarcinogenicityNon-carcinogens0.7905
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3719 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9856
hERG inhibition (predictor II)Non-inhibitor0.8419
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0029000000-1a5ed66ff895eeb127ce
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0129000000-a967b7f9e88a461e3db4
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01q9-2598000000-f71f4f9eb7c83ddf79f4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0029000000-13ff69b3abd31dde6bae

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Pyrazoles
Direct Parent
Phenylpyrazoles
Alternative Parents
Benzenesulfonamides / Benzenesulfonyl compounds / Toluenes / Organosulfonamides / Heteroaromatic compounds / Aminosulfonyl compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organofluorides
show 3 more
Substituents
Phenylpyrazole / Benzenesulfonamide / Benzenesulfonyl group / Toluene / Monocyclic benzene moiety / Organosulfonic acid amide / Benzenoid / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Sulfonyl
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, pyrazoles, sulfonamide (CHEBI:41423)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I: COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology. 2002 Jun;122(7):1913-23. [PubMed:12055598]
  2. Scheiman JM: Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med. 2002;69 Suppl 1:SI40-6. [PubMed:12086292]
  3. Reddy BS, Rao CV: Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol. 2002;21(2):155-64. [PubMed:12086402]
  4. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J: Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. 2002;25(7):537-44. [PubMed:12093311]
  5. Lu S, Zhang X, Badawi AF, El-Sohemy A, Archer MC: Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer Lett. 2002 Oct 8;184(1):7-12. [PubMed:12104042]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein serine/threonine kinase activity
Specific Function
Serine/threonine kinase which acts as a master kinase, phosphorylating and activating a subgroup of the AGC family of protein kinases. Its targets include: protein kinase B (PKB/AKT1, PKB/AKT2, PKB...
Gene Name
PDPK1
Uniprot ID
O15530
Uniprot Name
3-phosphoinositide-dependent protein kinase 1
Molecular Weight
63151.305 Da
References
  1. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS: 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 2004 Feb 15;64(4):1444-51. [PubMed:14973075]
  2. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS: From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004 Jun 15;64(12):4309-18. [PubMed:15205346]
  3. Tong Z, Wu X, Ovcharenko D, Zhu J, Chen CS, Kehrer JP: Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J. 2005 Oct 15;391(Pt 2):441-8. [PubMed:16060857]
  4. Li J, Zhu J, Melvin WS, Bekaii-Saab TS, Chen CS, Muscarella P: A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. J Gastrointest Surg. 2006 Feb;10(2):207-14. [PubMed:16455452]
  5. Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS: Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3. [PubMed:16887935]
Details
3. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101]
Details
4. Carbonic anhydrase 3
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA3
Uniprot ID
P07451
Uniprot Name
Carbonic anhydrase 3
Molecular Weight
29557.215 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Efflux transmembrane transporter activity
Specific Function
Drug efflux transporter present in a number of stem cells that acts as a regulator of cellular differentiation. Able to mediate efflux from cells of the rhodamine dye and of the therapeutic drug do...
Gene Name
ABCB5
Uniprot ID
Q2M3G0
Uniprot Name
ATP-binding cassette sub-family B member 5
Molecular Weight
138639.48 Da
References
  1. Pagliarulo V, Ancona P, Niso M, Colabufo NA, Contino M, Cormio L, Azzariti A, Pagliarulo A: The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. Mol Cancer. 2013 May 24;12:47. doi: 10.1186/1476-4598-12-47. [PubMed:23705854]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Pagliarulo V, Ancona P, Niso M, Colabufo NA, Contino M, Cormio L, Azzariti A, Pagliarulo A: The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. Mol Cancer. 2013 May 24;12:47. doi: 10.1186/1476-4598-12-47. [PubMed:23705854]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Pagliarulo V, Ancona P, Niso M, Colabufo NA, Contino M, Cormio L, Azzariti A, Pagliarulo A: The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. Mol Cancer. 2013 May 24;12:47. doi: 10.1186/1476-4598-12-47. [PubMed:23705854]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
2. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Davies NM, McLachlan AJ, Day RO, Williams KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000 Mar;38(3):225-42. [PubMed:10749518]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF: New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126. [PubMed:20167001]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74. [PubMed:11259318]
  6. Rodrigues AD: Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005 Nov;33(11):1567-75. Epub 2005 Aug 23. [PubMed:16118328]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K: Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003 Aug;74(2):130-7. [PubMed:12891223]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 13, 2005 07:24 / Updated on November 17, 2018 07:09